Mara Goldstein

Stock Analyst at Mizuho

(2.69)
# 1,885
Out of 4,853 analysts
77
Total ratings
43.1%
Success rate
5.64%
Average return

Stocks Rated by Mara Goldstein

Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32$30
Current: $6.57
Upside: +356.62%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30$10
Current: $1.80
Upside: +455.56%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9$8
Current: $6.18
Upside: +29.45%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51$42
Current: $9.63
Upside: +336.14%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59$50
Current: $9.12
Upside: +448.25%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $11.16
Upside: +303.23%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82$77
Current: $67.24
Upside: +14.52%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8$7
Current: $1.58
Upside: +344.44%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12$8
Current: $1.34
Upside: +497.01%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20$12
Current: $0.40
Upside: +2,936.44%
Reiterates: Neutral
Price Target: $6
Current: $0.67
Upside: +789.15%
Reiterates: Neutral
Price Target: $3.5
Current: $3.91
Upside: -10.49%
Reiterates: Buy
Price Target: $12
Current: $0.12
Upside: +9,891.67%
Upgrades: Buy
Price Target: $10$20
Current: $2.05
Upside: +875.61%
Reiterates: Buy
Price Target: $130
Current: $77.62
Upside: +67.48%
Maintains: Neutral
Price Target: $4$2
Current: $2.40
Upside: -16.67%
Maintains: Buy
Price Target: $18$12
Current: $2.26
Upside: +430.97%
Upgrades: Buy
Price Target: $9
Current: $0.29
Upside: +3,047.95%
Reiterates: Overweight
Price Target: $14$20
Current: $32.08
Upside: -37.66%
Downgrades: Neutral
Price Target: $34$48
Current: $7.40
Upside: +548.65%
Downgrades: Neutral
Price Target: n/a
Current: $19.53
Upside: -
Maintains: Overweight
Price Target: $12$14
Current: $3.64
Upside: +284.62%